These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18612313)

  • 1. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
    Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.
    Suttorp M; Claviez A; Bader P; Peters C; Gadner H; Ebell W; Dilloo D; Kremens B; Kabisch H; Führer M; Zintl F; Göbel U; Klingebiel T
    Klin Padiatr; 2009; 221(6):351-7. PubMed ID: 19890786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Morales-Toquero A; Gutiérrez-Aguirre CH; Vela-Ojeda J; García-Ruiz-Esparza MA; Manzano C; Karduss A; Sumoza A; de-Souza C; Miranda E; Giralt S;
    Bone Marrow Transplant; 2005 Dec; 36(12):1043-7. PubMed ID: 16247424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies for CML.
    Goldman JM
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):303-13. PubMed ID: 19959082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
    Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
    Klyuchnikov E; Kröger N; Brummendorf TH; Wiedemann B; Zander AR; Bacher U
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):301-10. PubMed ID: 19744571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
    Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
    Burke MJ; Willert J; Desai S; Kadota R
    Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
    Grigg A; Hughes T
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):795-807. PubMed ID: 16864049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.